CEACAM5 and neoplasm: Patients with CEA ≥ 5 ng/ml, PET maxSUV ≥ 3.2, CT tumor size ≥ 2.4 cm, and clinical nodal metastasis recur in HRS or multiple LRS at 55.9% within 5 years after surgery; therefore, these patients should receive aggressive neoadjuvant/adjuvant therapy.